Drug Type Small molecule drug |
Synonyms Relugolix/Estradiol/Norethisterone Acetate, AKP-022, Myfembree + [1] |
Target |
Action agonists, antagonists, inhibitors |
Mechanism ERs agonists(Estrogen receptors agonists), GnRHR antagonists(Gonadotropin-releasing hormone receptor antagonists), PR agonists(Progesterone receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United States (26 May 2021), |
Regulation- |
Molecular FormulaC29H27F2N7O5S |
InChIKeyAOMXMOCNKJTRQP-UHFFFAOYSA-N |
CAS Registry737789-87-6 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Pain | Canada | 17 Oct 2023 | |
Hemorrhage | Canada | 22 Sep 2023 | |
Endometriosis | United States | 05 Aug 2022 | |
Menorrhagia | United States | 26 May 2021 | |
Uterine Fibroids | United States | 26 May 2021 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Contraception | Phase 3 | United States | 18 Mar 2021 | |
Contraception | Phase 3 | Puerto Rico | 18 Mar 2021 | |
Pelvic Pain | Phase 2 | United States | 05 Apr 2024 | |
Pregnancy | Clinical | - | 01 Jan 2025 | |
Pregnancy Complications | Clinical | - | 01 Jan 2025 |
Phase 3 | 382 | (Relugolix Plus E2/NETA (Group A)) | skosijzweo = rtlqprugyq chlrfgqads (frrgjmkyee, lvgazhefcc - azwbgnaxyz) View more | - | 20 Apr 2022 | ||
Estradiol/norethindrone acetate placebo (Placebo (Group C)) | skosijzweo = voqftstebd chlrfgqads (frrgjmkyee, zdulbdqspw - lojdpgixew) View more | ||||||
Phase 3 | 388 | (Relugolix Plus E2/NETA (Group A)) | ifscztydoj = vgtpbquksj imysvouhyl (gzvhzjoxxq, tpygwwbqti - mqdzqjibmf) View more | - | 19 Apr 2022 | ||
Estradiol/norethindrone acetate placebo (Placebo (Group C)) | ifscztydoj = vyhyeqvmfw imysvouhyl (gzvhzjoxxq, wxjtzvqulw - rrrjpubbqi) View more |